NCT06889987 Bilateral Ultrasound Guided Intramuscular Quadratus Lumborum Plane Block Versus Bilateral Lateral Quadratus Lumborum Plane Block in Controlling Postoperative Pain in Cancer Patients Undergoing Open Nephrectomy
| NCT ID | NCT06889987 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Egypt |
| Condition | Bilateral |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-12-10 |
| Primary Completion | 2025-12-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-12-10 with a primary completion date of 2025-12-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the efficacy of bilateral ultrasound-guided intramuscular quadratus lumborum plane block (QL4) versus bilateral lateral quadratus lumborum plane block (QL1) in controlling postoperative pain in cancer patients undergoing open nephrectomy.
Eligibility Criteria
Inclusion Criteria: * Age from 18 to 65 years. * Both sexes. * American Society of Anesthesiology (ASA) physical status II-III. * Body mass index (BMI): (20- 40) kg/m2. * Type of surgery: midline incision for unilateral open nephrectomy. Exclusion Criteria: * Patient refusal. * Age \<18 years or \>65 years * BMI \<20 kg/m2 and \> 40 kg/m2 * Known sensitivity or contraindication to drugs used in the study * Contraindication to regional anesthesia, e.g. local infection at the introduction site, pre-existing peripheral neuropathies and coagulopathy. * Physical status ASA IV * Patients on chronic analgesic therapy (daily morphine ≥30 mg or equivalent dose of other opioids or tramadol or any medication for neuropathic pain) * Patients with a history of drug abuse * Patients with neuropsychiatric diseases; patients with a history of chronic pain syndromes that may enhance sensitivity to pain, for example, fibromyalgia * All patients who are going to have severe intra- or post-operative bleeding or will require postoperative mechanical ventilation are also excluded from the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06889987 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Bilateral. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06889987 currently recruiting?
Yes, NCT06889987 is actively recruiting participants. Contact the research team at dr.Ahmed.ismail93@gmail.com for enrollment information.
Where is the NCT06889987 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06889987 clinical trial?
NCT06889987 is sponsored by National Cancer Institute, Egypt. The trial plans to enroll 90 participants.